EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study Researchers found that when the drugs were used to treat dermatological conditions, the risk of acne was significantly higher than when they were used to treat other ailments. November 8, 2023 Martha Garcia Add Your Comments A new study suggests Xeljanz and similar drugs used to treat inflammation and autoimmune conditions, like ulcerative colitis and rheumatoid arthritis, may increase the risk of developing acne. Harvard researchers report that patients taking a class of drugs known as Janus Kinase (JAK) inhibitors, which includes blockbuster treatments like Xeljanz, Rinvoq and others, were four times more likely to experience acne than patients not taking the medications. Their findings were published on October 18 in the journal JAMA Dermatology. JAK inhibitors, which block the JAK enzymes in the body, are used to treat a wide variety of conditions ranging from autoimmune diseases like Crohn’s disease, rheumatoid arthritis, and alopecia, as well as COVID-19 and other inflammatory ailments. They are also commonly used to treat dermatological conditions, such as eczema and atopic dermatitis. Xeljanz, Rinvoq Acne Risks In this latest study, researchers from Harvard Medical School, Vanderbilt University, and other universities conducted a systematic review and meta-analysis of 25 unique studies, including phase 2 and 3 randomized clinical trials involving nearly 11,000 participants. They focused on the use of JAK inhibitors, including JAK1, combination JAK1 and JAK2, and tyrosine kinase 2-specific inhibitor drugs, and the possible side effects of acne. According to the findings, patients taking JAK inhibitors were 3.83 times more likely to have acne than patients on a placebo. However, the rates varied between the types of JAK inhibitors used. The findings indicate patients taking JAK1 and combo JAK1 and JAK2 inhibitors are more likely to have acne side effects. The researchers found that patients taking JAK1 inhibitors, like Imbruvica and Zydelig, faced nearly five times the risk of having acne. While those taking a combination of JAK1 and JAK2 inhibitors, like Rinvoq and Xeljanz, faced a nearly four-fold increase in acne. Participants taking tyrosine kinase 2-specific inhibitor treatments, like Gleevec and Sprycel, were only 2.5 times more likely to have acne. Patients taking Cibinqo faced more than a 13-fold risk of getting acne, those taking Olumiant and Rinvoq, nearly five times the risk, the data indicates. The risk of having acne as a side effect was more common among patients in drug trials where the drug was used for dermatologic conditions, compared to other types of conditions, like arthritis, ulcerative colitis, or alopecia, the researchers noted. However, the study’s authors warned that more research is needed to determine the full acne risks associated with these drugs, as well as the mechanism of action that causes the skin reactions. “These findings suggest that patients should be properly counseled on the potential adverse effects of acne before beginning treatment with JAK inhibitors,” the researchers advised. Xeljanz Cancer Concerns and Lawsuits The findings may add to concerns that have emerged over other side effects of Xeljanz, Rinvoq and other similar JAK inhibtors, which have been linked to blood clots and cancer risks in recent years. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Xeljanz (tofacitinib) was introduced by Pfizer as the first JAK inhibitor in 2012, joining the lucrative market for treatments of individuals with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. The drug was considered revolutionary, and quickly gained the upper-hand on alternative TNF inhibitors, which are administered by shot or infusion. As more data has become available, concerns about potential Xeljanz cancer risks and other side effects began to emerge in early 2021, after preliminary data from a post-marketing study linked Xeljanz to an increased risk of cancer, heart attacks, strokes and deadly blood clots. These findings have resulted in a number of Xeljanz lawsuits being filed by former users diagnosed with cancer, pulmonary embolism and other injuries, alleging that drug makers failed to adequately research the side effects of JAK inhibitors and warn about potential risks compared to older TNF inhibitors. Although each of the complaints raise similar questions of fact and law, there are not currently any consolidated pretrial proceedings in the federal court system, and each of the lawsuits is moving forward on an individual tract. The number of lawsuits are projected to grow throughout the rest of 2023 as Xeljanz lawyers continue to investigate and file new claims for individuals who took Xeljanz and Xeljanz XR, or any of the JAK inhibitor drugs and suffered; Pulmonary Embolism (PE) Deep Vein Thrombosis (DVT) Ischemic or Embolic Stroke (do not accept mini-strokes) Heart Attack Cancer or Lymphoma Diagnosis Hospitalization due to another blood clot injury Tags: Acne, Cancer, Cibingo, Olumiant, Pfizer, Rheumatoid Arthritis, Rinvoq, Skin Reactions, Xeljanz, Zydelig More Xeljanz Lawsuit Stories Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023 Drugs Advertised on TV Often Have Low Therapeutic Value, Study Finds January 26, 2023 EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks November 4, 2022 1 Comments Mary December 11, 2024 My heart stopped one year after starting Rinvoq. Please see comment below. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (Posted: today) In the six months since a Bard hernia mesh settlement agreement was reached, at least two dozen new lawsuits have been brought, as the implants continue to fail and require revision surgery. MORE ABOUT: HERNIA MESH LAWSUITHernia Surgery Malpractice Lawsuit Cleared To Move Forward Over Botched Procedure (03/21/2025)Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (03/14/2025)Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025) Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: yesterday) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025) Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: 2 days ago) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors May 1, 2023
EMA Calls for Restricted Use of Xeljanz, Rinvoq, Similar Drugs Due to Heart, Cancer, Blood Clot and Infection Risks November 4, 2022
New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (Posted: today) In the six months since a Bard hernia mesh settlement agreement was reached, at least two dozen new lawsuits have been brought, as the implants continue to fail and require revision surgery. MORE ABOUT: HERNIA MESH LAWSUITHernia Surgery Malpractice Lawsuit Cleared To Move Forward Over Botched Procedure (03/21/2025)Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (03/14/2025)Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)
Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: yesterday) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: 2 days ago) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)